Literature DB >> 23904761

Are two-centimeter breast cancers large or small?

S A Narod1, J Iqbal, A Jakubowska, T Huzarski, P Sun, C Cybulski, J Gronwald, T Byrski, J Lubinski.   

Abstract

BACKGROUND: Node-negative breast cancers from 2 cm to 5 cm in size are classified as stage ii, and smaller cancers, as stage i. We sought to determine if the prognosis of women with a breast cancer exactly 2 cm in size more closely resembles that of women with a stage i or a stage ii breast cancer.
METHODS: Using a cohort of 4265 young women with breast cancer, we compared the 10-year breast cancer mortality rates for women who had a tumour 0.1-1.9 cm, exactly 2.0 cm, and 2.1-2.9 cm.
RESULTS: In the first 3 years after diagnosis, the survival pattern of women with a 2.0-cm breast cancer was nearly identical to that of women with a larger cancer (2.1-3.0 cm). From year 3 to year 10, the relative survival of women with a 2.0-cm breast cancer was improved and nearly identical to that of women with a smaller cancer. The 10-year survival rate was 89.3% for women with tumours less than 20 mm, 86.1% for women with tumours equal to 20 mm, and 81.2% for women with 21-mm to 29-mm tumours.
CONCLUSIONS: For young women with small breast cancers, the relative mortality from breast cancer is dynamic with increasing tumour size and varies with time from diagnosis.

Entities:  

Keywords:  Breast cancer; stage; survival

Year:  2013        PMID: 23904761      PMCID: PMC3728051          DOI: 10.3747/co.20.1364

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  16 in total

1.  Primary tumor size. Relevance to breast cancer survival.

Authors:  J P Crowe; N H Gordon; R R Shenk; R M Zollinger; D J Brumberg; J M Shuck
Journal:  Arch Surg       Date:  1992-08

2.  A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.

Authors:  P R Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-03       Impact factor: 44.544

3.  The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999.

Authors:  Elena B Elkin; Clifford Hudis; Colin B Begg; Deborah Schrag
Journal:  Cancer       Date:  2005-09-15       Impact factor: 6.860

4.  Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials.

Authors:  Irene L Wapnir; Stewart J Anderson; Eleftherios P Mamounas; Charles E Geyer; Jong-Hyeon Jeong; Elizabeth Tan-Chiu; Bernard Fisher; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

5.  Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Authors:  Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

6.  Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years.

Authors:  P P Rosen; S Groshen; P E Saigo; D W Kinne; S Hellman
Journal:  J Clin Oncol       Date:  1989-09       Impact factor: 44.544

7.  Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy?

Authors:  Steven A Narod; Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Andre Robidoux; Nadine Tung; Elizabeth Gaughan; Charmaine Kim-Sing; Olufunmilayo I Olopade; William D Foulkes; Mark Robson; Kenneth Offit; Ania Jakubowska; Tomasz Byrski; Tomasz Huzarski; Ping Sun; Jan Lubinski
Journal:  Breast Cancer Res Treat       Date:  2013-02-06       Impact factor: 4.872

8.  Residual risk of breast cancer recurrence 5 years after adjuvant therapy.

Authors:  Abenaa M Brewster; Gabriel N Hortobagyi; Kristine R Broglio; Shu-Wan Kau; Cesar A Santa-Maria; Banu Arun; Aman U Buzdar; Daniel J Booser; Vincente Valero; Melissa Bondy; Francisco J Esteva
Journal:  J Natl Cancer Inst       Date:  2008-08-11       Impact factor: 13.506

9.  Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years.

Authors:  Laura Cortesi; Luigi Marcheselli; Valentina Guarneri; Claudia Cirilli; Barbara Braghiroli; Angela Toss; Milena Sant; Guido Ficarra; Pier Franco Conte; Massimo Federico
Journal:  Int J Cancer       Date:  2012-09-21       Impact factor: 7.396

10.  Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.

Authors:  Pratyaksha Wirapati; Christos Sotiriou; Susanne Kunkel; Pierre Farmer; Sylvain Pradervand; Benjamin Haibe-Kains; Christine Desmedt; Michail Ignatiadis; Thierry Sengstag; Frédéric Schütz; Darlene R Goldstein; Martine Piccart; Mauro Delorenzi
Journal:  Breast Cancer Res       Date:  2008-07-28       Impact factor: 6.466

View more
  2 in total

1.  Virtual assessment of stereoscopic viewing of digital breast tomosynthesis projection images.

Authors:  Gezheng Wen; Ho-Chang Chang; Jacob Reinhold; Joseph Y Lo; Mia K Markey
Journal:  J Med Imaging (Bellingham)       Date:  2018-01-17

2.  3D Disease Modelling of Hard and Soft Cancer Using PHA-Based Scaffolds.

Authors:  Akanksha Tomar; Pinar Uysal-Onganer; Pooja Basnett; Uttam Pati; Ipsita Roy
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.